Lenvatinib Mesylate Capsules are indicated for the treatment of unresectable hepatocellular carcinoma not previously treated with systemic therapy. Lenvatinib Mesylate Capsules are mainly indicated for the treatment of unresectable hepatocellular carcinoma that has not received previous systemic treatment, and is the first-line treatment for hepatocellular carcinoma. Adverse reactions of Lenvatinib Mesylate Capsules are more frequent, mainly including elevated blood pressure, proteinuria, renal failure and renal insufficiency, cardiac dysfunction such as congestive heart failure, liver toxicity, arterial embolism, hemorrhage, gastrointestinal discomfort or even gastrointestinal perforation, diarrhea and so on, so you should check liver and kidney function, urine routine and so on, and pay attention to controlling the blood pressure and so on during the period of taking this drug. For the components of this product allergy, pregnant women, lactating women with reproductive plans prohibit the use of this drug, under the guidance of the clinician to take this drug, do not blindly use the drug, in order to avoid the occurrence of adverse reactions.